购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Others
    (5)
TargetMol | Tags 通过 货期 筛选
  • 5日内发货
    (1)
  • 35日内发货
    (3)
  • 8-10周
    (1)
  • 10-14周
    (1)
筛选
搜索结果
TargetMol产品目录中 "

l moses

"的结果
  • 抑制剂&激动剂
    5
    TargetMol | Inhibitors_Agonists
  • L-Moses
    L-45
    T11796L2079885-05-3
    L-45 is the first potent and cell-active bromodomain (Brd) inhibitor of p300 CBP-associated factor (PCAF) (Kd: 126±15 nM).
    • 待询
    5日内发货
    规格
    数量
  • L Moses dihydrochloride
    T36109
    High affinity and selective cell-permeable p300/CBP-associated factor (PCAF) inhibitor (Ki = 47 nM). Exhibits no significant activity against a panel of 48 other bromodomains except GCN5 (Kd = 600 nM). Exhibits >4500-fold selectivity for PCAF over BRD4. Also exhibits metabolic stability in mouse and human liver microsomes and no observable cytotoxicity in peripheral blood mononuclear cells (PBMC). Moustakim et al (2017) Discovery of a PCAF bromodomain chemical probe. Angew.Chem.Int.Ed. 56 827 PMID:27966810
    • 待估
    35日内发货
    规格
    数量
  • l-moses dihydrochloride
    T62424
    L-Moses (L-45) dihydrochloride 是一个有效的、选择性 p300 CBP 相关因子 (PCAF) 溴结构域 (Brd) 抑制剂 (Kd: 126 nM)。
    • ¥ 35000
    10-14周
    规格
    数量
  • Deoxy Donepezil (hydrochloride)
    T358311034439-57-0
    Deoxy donepezil is a potential impurity found in bulk preparations of the acetylcholinesterase inhibitor donepezil .1It is produced as a by-product during donepezil synthesis.2 1.Krishna Reddy, K.V.S.R., Moses Babu, J., Anil Kumar, P., et al.Identification and characterization of potential impurities of donepezilJ. Pharm. Biomed. Anal.35(5)1047-1058(2004) 2.Krizmanic, I., Lerman, L., Samardzic, Z., et al.Impurities of donepezil(2009)
    • ¥ 1190
    35日内发货
    规格
    数量
  • D-DOPA
    T376055796-17-8
    D-DOPA is an enantiomer of the dopamine precursor L-DOPA . It can be converted to L-DOPAviasequential oxidation and transamination, which are mediated by D-amino acid oxidase (DAAO) and DOPA transaminase, respectively, in rat kidney homogenates.1It reduces the number of dopaminergic neurons in primary rat embryonic mesencephalic cultures in a concentration-dependent manner.2Intraventricular administration of D-DOPA (200 μg/animal) increases striatal dopamine levels in rats.3D-DOPA (20 mg/kg, i.p.) induces contralateral turns in a rat model of Parkinson's disease induced by 6-OHDA .4 1.Wu, M., Zhou, X.-J., Konno, R., et al.D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminaseClin. Exp. Pharmacol. Physiol.33(11)1042-1046(2006) 2.Ling, Z.-D., Pieri, S.C., and Carvey, P.M.Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neuronsClin. Neuropharmacol.19(4)360-365(1996) 3.Karoum, F., Freed, W.J., Chuang, L.-W., et al.D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in ratsBrain Res.440(1)190-194(1988) 4.Moses, J., Siddiqui, A., and Silverman, P.B.Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian ratNeurosci. Lett.218(3)145-148(1996)
    • 待估
    35日内发货
    规格
    数量